Janssen Presents First Results from Dual Bispecific : vimars

BEERSE, BELGIUM, June 03, 2023 (GLOBE NEWSWIRE) -- The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the first results from...

Related Keywords

United States , Chicago , Illinois , Israel , Beerse , Region Flamande , Belgium , American , Edmond Chan , Yael Cohen , Arnob Banerjee , Companies Of Johnson , Committee For Medicinal Products Human Use , Janssen Research Development , Hematology Institute Tel , Early Development Oncology , Aviv Sourasky Medical Center , American Society Of Clinical Oncology , Janssen Pharmaceutical Companies Of Johnson , European Medicines Agency , American Cancer Society , Johnson , None Of The Janssen Pharmaceutical Companies , Exchange Commission , European Commission , Janssen Pharmaceutical Companies , Clinical Oncology , Annual Meeting , Myeloma Unit , Confidence Interval , Not Estimable , Senior Director , Area Lead Haematology , Global Medical Head , Janssen Research , Medicinal Products , Human Use , Breakthrough Therapy Designation , Orphan Drug Designation , Multiple Myeloma , Pharmaceutical Companies , Infectious Diseases , Janssen Cilag Limited , Private Securities Litigation Reform Act , Janssen Pharmaceutica , Janssen Pharmaceutical , Annual Report , Note Regarding Forward Looking , Quarterly Reports , Results From , With Teclistamab , Simultaneously Targeting , Refractory Multiple Myeloma , Participants With Relapsed , Refractory Multiple , Participants With Multiple Myeloma , Subcutaneous Daratumumab Regimens , Bispecifict Cell Redirection Antibodies , Daratumumab Subcutaneously , Versus Daratumumab , Bispecific Antibody , Teclistamab Each , Combination With , Programmed Cell Death , Study Comparing Talquetamab , Combination With Daratumumab , Pomalidomide Versus Daratumumab , Combination With Pomalidomide , Today Population Factsheets , Janssen Emea ,